Group 1: Healthcare Policy Changes - The new national medical insurance drug list has been implemented, adding 114 new drugs covering areas such as cancer, diabetes, and rare diseases [2] - A new batch of centralized procurement for 55 drugs will take place in February 2026, including medications for allergies, diabetes, and antiviral treatments [2] - The National Health Commission mandates that primary healthcare institutions must be equipped with at least five categories of antihypertensive drugs starting March 1, 2026 [3] Group 2: Maternal and Child Health Initiatives - From July 1, 2025, Jiangsu Province has implemented a "zero out-of-pocket" policy for hospital deliveries, with the aim to expand this benefit nationwide by 2026 [4] - The 2026 initiatives include increasing maternity subsidies, expanding coverage for flexible workers and migrant workers, and integrating suitable pain relief methods into medical insurance [4] Group 3: Long-term Care Insurance Developments - Long-term care insurance is currently focused on severely disabled individuals, with plans to include moderately disabled individuals by 2026 [6] - An action plan to enhance elderly care services will be launched, establishing geriatric departments in hospitals and extending care services to communities and homes [6] Group 4: Medical Service Accessibility and Efficiency - The medical imaging cloud platform will expand its cross-province data sharing capabilities, aiming for over 300 mutual recognition projects among medical institutions by the end of 2027 [8] - Starting January 1, 2026, all medical institutions must implement full collection and upload of drug traceability codes to combat illegal use of medical insurance funds [8]

Group 1: New Drug Policies - The new national medical insurance drug list has been implemented, adding 114 new drugs covering areas such as cancer, diabetes, and rare diseases [2] - A new batch of centralized procurement for 55 drugs will take place in February 2026, including medications for allergies, diabetes, and antiviral treatments [2] - The first version of the commercial insurance innovative drug directory has been released, providing 19 innovative drugs for reference in product design [2] Group 2: Maternal and Child Health - From July 1, 2025, Jiangsu province implemented a "zero out-of-pocket" policy for hospital deliveries, with the aim to expand this benefit nationwide by 2026 [4] - The 2026 initiatives include increasing maternity subsidies, expanding coverage for flexible workers and migrant workers, and incorporating suitable pain relief methods into medical insurance [4] - A series of measures are being introduced to support child health and development, including direct disbursement of maternity benefits to insured individuals [4] Group 3: Elderly Care and Long-term Insurance - Long-term care insurance is expanding to cover more individuals, with a focus on enhancing elderly care services starting in 2026 [6][7] - The initiative includes establishing geriatric departments in hospitals and extending care services to community and home settings [6] Group 4: Healthcare Accessibility and Insurance Fund Security - The medical imaging cloud platform will enhance the sharing of diagnostic data across provinces, aiming for over 300 mutual recognition projects by the end of 2027 [8] - The implementation of cross-province use of employee medical insurance accounts will be fully realized in 2026 [8] - A new drug traceability system will be enforced from January 1, 2026, to combat illegal activities related to medical insurance funds [8]

Investment Rating - The report suggests a positive outlook for the pharmacy and traditional Chinese medicine sectors, anticipating a recovery in 2026 after a weak performance in 2025 [2][5]. Core Insights - The pharmacy sector is expected to benefit from market consolidation, with leading companies likely to increase their market share through mergers and acquisitions during the industry clearing phase [3][11]. - The traditional Chinese medicine sector is projected to stabilize and potentially recover, driven by an increase in flu incidence and the upcoming update of the essential drug list [57][60]. Summary by Sections Pharmacy Sector - **Market Review**: The pharmacy sector faced significant challenges in 2025, with a decline in same-store sales and an overall reduction in the number of operating stores since Q4 2024 [5][20]. - **Policy Environment**: Regulatory measures are promoting a more compliant and healthier industry ecosystem, which is expected to benefit leading companies [14][15]. - **Market Size**: In the first ten months of 2025, the sales scale of physical pharmacies was 501.3 billion yuan, a year-on-year decrease of 1.6%, primarily due to a decline in non-pharmaceutical sales [16][21]. - **Competitive Landscape**: The number of pharmacies in China reached approximately 684,000 by the end of 2024, with a notable increase in store closures, particularly among smaller chains [20][24]. - **Marginal Performance**: There has been a slight recovery in retail sales data, with leading companies showing improved performance through cost reduction and efficiency measures [32][34]. - **Outlook for 2026**: Focus on market consolidation and the development of non-pharmaceutical products is recommended, as leading companies are expected to enhance their market share [44][52]. Traditional Chinese Medicine Sector - **Market Review**: The traditional Chinese medicine sector experienced overall weak performance in 2025, with some companies seeing temporary valuation increases due to innovative pipelines [57][58]. - **In-Hospital Opportunities**: The upcoming update of the essential drug list is expected to benefit companies with products that have the potential to be included [60]. - **Out-of-Hospital Opportunities**: An increase in flu incidence in Q4 2025 is anticipated to aid in inventory digestion, with some companies expected to see improved performance [60]. - **High Dividend Stocks**: Companies such as Lingrui Pharmaceutical, Jichuan Pharmaceutical, and Dong'e Ejiao are highlighted as stable high-dividend investment opportunities [60].

Core Insights - Recent news highlights a surge in collective procurement (集采) activities in China, particularly in Henan province, where 34 high-demand and high-value drug varieties are set for a new round of procurement [1][17] - The national procurement signal indicates that over 140 drug varieties meet the competitive criteria of having seven or more companies, with notable participation from companies like Qilu, Yuanda, and Beite [1][13] Group 1: Procurement Details - The Henan provincial healthcare bureau has released a draft for the procurement of 34 drug varieties, focusing on alternatives that are high in usage and financial value [1][17] - The procurement list has been optimized, removing 15 drug varieties from the previous notification, indicating a refined focus on quality and market needs [3][20] - The procurement method categorizes oral solid preparations and injectables into two groups (A and B) based on quality, with specific selection criteria for each group [3][20] Group 2: Market Impact - The proposed procurement includes 10 Class A and 13 Class B drugs, with injectables dominating the list, reflecting a significant market shift [4][22] - The total sales for the selected drugs in Henan's public hospitals are projected to exceed 4 billion yuan in 2024 and 2 billion yuan in the first half of 2025 [10][28] - Notable drugs in the procurement list include Cisplatin and Erythromycin, both of which are essential in cancer treatment and infection management, respectively [6][24] Group 3: Competitive Landscape - The competitive landscape is expected to intensify, with companies like Qilu and Ruijun leading in market share for key products such as the analgesic Parecoxib, which is projected to have significant sales growth [10][28] - The sales of Ubenimex, an immune enhancer, have shown remarkable growth, with a projected increase of over 7779% in 2024, indicating strong market demand [7][25] - The overall sales scale in Henan's public hospitals has consistently remained above 15.8 billion yuan from 2021 to 2024, with a growth rate of 7.02% expected in the first half of 2025 [10][29]

年末各个地方集采仍在持续开展。 同期值得注意的是，推进的河北牵头京津冀赣化药集采规模再创新高，187个纳入品种中不乏水飞蓟 宾、复方氨酚烷胺、塞替派等重磅产品。其中水飞蓟宾胶囊2024年销售额6.98亿元，2025年上半年达 3.31亿元；维生素D滴剂作为首年约定采购量最大的品种，仅河北、江西两省填报总量就接近2400万 瓶，2024年销售额达18.88亿元。 2025 年末，地方联盟集采进入集中落地期，多省联动采购模式持续扩容，纳入品种均聚焦临床用量 大、市场规模高的核心品类，形成 "国家集采补位 + 地方特色覆盖" 的全方位采购体系。 本月，地方药品集采密集落地——河南牵头34种药品省际联盟集采、京津冀赣化学药品集中带量采购、 河北联盟集采到期接续采购等多项举措接连推进，地方联盟集采的扩面提速态势显著。 此外，国家医保局年初已明确规划，2025年将在地方层面开展具备专业特色的全国联盟采购预计达到20 个左右，包括中成药、中药饮片以及高值耗材等，预计2025年国家和联盟组织开展的药品集采品种将达 到700个。 本月初，河南省医保局启动省际联盟集采，覆盖 34 个市场关注度较高的品种，剂型分布呈现 "注射剂 ...

Core Viewpoint - The company Fangsheng Pharmaceutical is initiating the liquidation of five subsidiaries that have not been operational or have ceased operations, following the previous liquidation of eight companies within four months, totaling thirteen companies [1][3][4]. Group 1: Company Actions - Fangsheng Pharmaceutical announced the liquidation of five subsidiaries, including Hunan Fangtai No. 2 to No. 5 Management Partnership and Hunan Fangsheng Tang Traditional Chinese Medicine Technology Co., Ltd. [3][16]. - The registered capital of these companies ranges from 8.78 million yuan (Fangtai No. 5) to 30 million yuan (Fangsheng Tang) [3][16]. - The company aims to reduce management costs and optimize resource allocation to enhance operational efficiency, consistent with the reasons for the previous liquidation [4][17]. Group 2: Financial Performance - In 2024, Fangsheng Pharmaceutical achieved a revenue of 1.777 billion yuan, a year-on-year increase of 9.15%, and a net profit attributable to shareholders of 255 million yuan, up 36.61% [6][18]. - The first three quarters of 2025 saw a net profit of 268 million yuan, representing a year-on-year growth of 17.60% [6][18]. - However, the medical business and other segments experienced a significant revenue decline of 41.12% to 76.96 million yuan in 2024, primarily due to the exit of three companies from the consolidated financial statements [6][18]. Group 3: Business Structure and Challenges - The company’s core products include various medications, with some experiencing revenue declines due to centralized procurement price reductions and the divestiture of pharmaceutical commercial operations [20][22]. - Despite the growth in core product sales, the overall revenue growth is hindered by price reductions and the exit of certain business segments [20][22]. - Fangsheng Pharmaceutical's total market value as of December 17 was 4.878 billion yuan, which is below the industry median, and its revenue of 1.777 billion yuan is only 35% of the industry average [22][23].

Investment Rating - The report assigns an "Accumulate" rating for the company for the first time [1] Core Views - The company has undergone a strategic transformation from a single focus on orthopedics to multiple therapeutic areas including cardiovascular, nutritional supplements, and electrolyte regulation. The core strategy is centered around "product supremacy" through a "self-research + collaboration" model to enrich the product pipeline [6][14] - In the first half of 2025, the company achieved revenue of 1.0995 billion yuan, with nutritional drugs contributing 43.88% and cardiovascular drugs 27.99% to total revenue. The company has a stable shareholding structure with Shen Zhenyu as the actual controller [6][14] - The company has shown a gradual recovery in performance, with a net profit of 244 million yuan in Q3 2025, representing a year-on-year growth of 32.85%, establishing a healthy operating pattern characterized by low debt and high profitability resilience [6][14] Financial Performance - The company’s projected revenues for 2025-2027 are 2,252.80 million, 2,392.24 million, and 2,637.93 million yuan, with growth rates of -7.70%, 6.19%, and 10.27% respectively. The projected net profits for the same period are 254.40 million, 288.74 million, and 348.65 million yuan, with growth rates of 9.30%, 13.50%, and 20.75% respectively [7] - The current market capitalization corresponds to a PE ratio of 28.25 for 2025, 24.89 for 2026, and 20.61 for 2027, indicating a favorable valuation outlook as the company navigates the pressures of centralized procurement [6][7] Industry Analysis - The global pharmaceutical market is expected to reach 1.9 trillion USD by 2027, with China's market share anticipated to continue increasing. Innovative drug technologies such as ADC, bispecific antibodies, and CGT are projected to be core growth engines [6][14] - The industry is currently in a dual-track development phase characterized by the normalization of centralized procurement and supportive policies for innovative drugs. The company’s core products have a high market share and align well with industry trends, indicating strong adaptability [6][14]

Group 1: Company Overview and Strategy - Hunan Jiutian Pharmaceutical Co., Ltd. is focusing on expanding its market presence through a multi-channel strategy and brand enhancement initiatives, including the launch of the "Jiutian Zhen Tong Xian Sheng" branding campaign on December 6, 2025 [2][3] - The company aims to strengthen its product pipeline by increasing R&D investments and introducing new products, while also leveraging its integrated supply chain to control costs and ensure product quality [3][4] Group 2: Product Specifics and Market Response - The company’s key product, Loxoprofen Sodium Gel Patch, has been selected in the 11th round of national drug centralized procurement at prices of ¥17.88 for 4 patches, ¥26.82 for 6 patches, and ¥35.76 for 8 patches, with a total planned selection of approximately 30.12 million patches [5] - Following the price reduction from centralized procurement, the company anticipates a potential increase in sales volume for Loxoprofen Sodium Gel Patch, contingent on market conditions post-implementation [5] Group 3: Mergers and Acquisitions - The company has acquired a 67% stake in Hunan Nona Pharmaceutical Technology Co., Ltd., which includes 67 drug licenses, enhancing its product offerings and market stability [3][4] - This acquisition is expected to fill potential sales gaps from the centralized procurement of Loxoprofen Sodium Gel Patch and diversify the product range with unique offerings like the Daiwen Moxibustion Patch [3] Group 4: Innovation and R&D Focus - The company is transitioning towards innovative drug development, establishing multiple R&D centers and focusing on various drug forms and cooperative models to expedite the development of new drugs [4][6] - Current R&D efforts are concentrated on oncology and chronic disease treatments, utilizing small molecules, peptides, and other advanced drug forms to build a robust pipeline [4][6] Group 5: Future Product Development - The JIJ02 gel is expected to complete Phase I clinical trials in the first half of 2026, with plans to initiate Phase II trials thereafter [7] - The company is optimistic about the market prospects for Ketoprofen Gel, which was approved in 2023 and included in the national medical insurance directory, and is implementing new sales strategies to enhance market penetration [7]

Core Viewpoint - The demand for flu medication, particularly Oseltamivir, has surged with the onset of the flu season, leading to significant sales growth. Dongyangguang Pharmaceutical has recently increased the price of its new Oseltamivir granules after opting out of centralized procurement [1] Group 1: Market Dynamics - Oseltamivir is currently the highest-selling flu medication and was notably absent from the 11th batch of national centralized procurement results, which surprised the industry. Dongyangguang Pharmaceutical, a major player, did not win a bid, with Hunan Huize and Chengdu First Pharmaceutical being selected instead [1] - Reports suggest that Dongyangguang Pharmaceutical did not lose the bid but chose to withdraw by quoting a high price [1] Group 2: Company Performance - Dongyangguang Pharmaceutical's core product, "Kewai" (Oseltamivir phosphate), once held a 90% market share in China. In 2023, it generated revenue of 5.546 billion yuan, accounting for nearly 90% of the company's total revenue [1] - However, projections for 2024 indicate a decline in sales revenue for this product to 2.58 billion yuan, reducing its revenue contribution to 64.2% [1] Group 3: Competitive Landscape - The expiration of Oseltamivir's patent has intensified market competition, with over 40 companies, including listed firms such as Shuanglu Pharmaceutical and Kelun Pharmaceutical, now selling the drug [1]

Core Viewpoint - The National Healthcare Security Administration (NHSA) is committed to institutionalizing and regularizing the drug procurement process to enhance the organization of medical procurement at both national and local levels [1] Group 1: Drug Procurement Optimization - The NHSA will continuously optimize drug procurement measures, focusing on clinical needs and ensuring quality and supply security [1] - There is an emphasis on increasing the accessibility of procured drugs to grassroots medical institutions, private medical facilities, and retail pharmacies [1] Group 2: Direct Settlement and Efficiency - The NHSA aims to accelerate direct settlement between medical insurance and pharmaceutical companies [1] - The goal is to make medication use more secure and reassuring for the public [1]